CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from the Canadian Institutes of Health Research (CIHR) to support the CCTG PR26 (TRIPLE-SWITCH) prostate clinical trial.
Plasma versus tissue tumor mutational burden as Biomarkers of Durvalumab plus Tremelimumab response in patients with metastatic colorectal cancer in the CO26 trial.
Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the CCTG LY12 clinical trial
The CEC6 trial, a Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant pcv chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low-grade glioma, has closed to further accrual as the study has met the target sample size.
The New Investigator Clinical Trials Course (NICTC) is fast approaching and has already reached the maximum registration. The course will be held from August 21st to the 23rd at the Donald Gordon Hotel and Conference Centre in Kingston, Ontario.
NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
